Both conditions are associated with extensive lysosomal CE and triglyceride accumulation in multiple tissues,14 and CE storage disease subjects develop premature atherosclerosis.15–21 Injection of recombinant LAL in low-density lipoprotein (LDL) receptor–deficient atherosclerotic mice prevented early atheroma formation and reduced the number of late-stage lesions,22 while injections of recombinant LAL into LAL-deficient mice reduced cholesterol and triglyceride levels in multiple tissues.23–26. The gene discussed is LIPA; the disease is atherosclerosis.